.png)
GRAIL
GRAIL Mission, Purpose & Impact
Frequently Asked Questions
GRAIL's mission is reflected in how the company develops its technology, conducts clinical research and works to expand access to multi-cancer early detection. Rather than focusing solely on product development, GRAIL invests in large-scale clinical studies, scientific partnerships and evidence generation to help improve cancer screening and patient outcomes. Employees across science, engineering, clinical and commercial teams contribute to advancing technologies that have the potential to detect cancers before symptoms appear.
- Developing multi-cancer early detection technology: GRAIL developed Galleri, a blood test designed to detect a shared cancer signal across more than 50 types of cancer, including many that currently lack recommended screening tests. The test combines next-generation sequencing, machine learning and genomic analysis to identify cancer signals from a single blood sample while also predicting the cancer signal's origin to help guide follow-up care.
- Building one of the largest clinical evidence programs in cancer screening: GRAIL has invested in one of the largest clinical development programs for multi-cancer early detection, enrolling hundreds of thousands of participants across studies including PATHFINDER, NHS-Galleri and REFLECTION. These studies are designed to evaluate how multi-cancer early detection can complement existing screening approaches and improve earlier diagnosis across diverse populations.
- Expanding access through partnerships: GRAIL works with healthcare systems, providers, employers and research organizations to increase access to early cancer detection. The company has partnered with the UK's National Health Service (NHS) on the landmark NHS-Galleri trial and continues collaborating with health systems across the United States to evaluate and expand the use of Galleri in clinical practice.
- Employees contributing to meaningful impact: Employees describe GRAIL as a place where they can apply science and technology to work with real-world significance. One employee shared that beyond the "rewarding work and constant learning," one of the most meaningful aspects of their experience was helping build and lead a new team while contributing to GRAIL's data platform and real-world evidence strategy.
- Focused on long-term impact: GRAIL continues investing in advancing multi-cancer early detection and expanding access to its technology around the world. This long-term commitment reflects GRAIL's focus on improving cancer care through continued scientific innovation and evidence generation.
- External signals:
- Scientific leadership: Independent industry coverage recognizes GRAIL as a leading company advancing the field of multi-cancer early detection through large-scale clinical research and genomic innovation. (GenomeWeb; Fierce Biotech)
- Landmark clinical research: GRAIL's NHS-Galleri trial is one of the world's largest studies evaluating multi-cancer early detection in a population screening setting. (NHS England)
- Growing clinical evidence: Independent coverage highlights GRAIL's continued investment in clinical validation and evidence generation to support broader adoption of early cancer detection technologies. (GenomeWeb; Fierce Biotech)
Bottom line: GRAIL brings its mission to life by combining cutting-edge science, large-scale clinical research and strategic partnerships to advance earlier cancer detection. From developing Galleri to generating extensive clinical evidence and expanding patient access, the company's work reflects a long-term commitment to improving cancer care and outcomes worldwide.
GRAIL seeks to make a difference by advancing technologies that have the potential to detect cancer earlier, when treatment is often more effective. Beyond developing Galleri, the company's impact extends through large-scale clinical research, partnerships with healthcare organizations and ongoing investments in expanding access to multi-cancer early detection. By combining genomics, artificial intelligence and clinical science, GRAIL aims to improve cancer outcomes for patients while helping shape the future of cancer screening worldwide.
- Expanding access to earlier cancer detection: GRAIL's primary contribution is developing Galleri, a multi-cancer early detection blood test designed to identify a shared cancer signal across more than 50 cancer types, including many without recommended screening tests. The company continues working with healthcare providers and health systems to make earlier cancer detection more accessible to eligible patients.
- Advancing cancer research: GRAIL has launched one of the largest clinical development programs in the field of multi-cancer early detection, enrolling hundreds of thousands of participants through studies such as PATHFINDER, NHS-Galleri and REFLECTION. These studies help generate the clinical evidence needed to evaluate how multi-cancer early detection can complement existing screening programs and improve patient outcomes.
- Collaborating with healthcare organizations: GRAIL partners with hospitals, healthcare providers, research institutions and public health organizations to advance cancer detection research and improve access to innovative screening technologies. Its collaboration with NHS England on the NHS-Galleri trial represents one of the largest population-based evaluations of multi-cancer early detection in the world.
- Creating meaningful opportunities for employees to make an impact: Employees contribute to work with tangible societal impact across science, engineering, clinical research and commercial functions. One employee shared that beyond the "rewarding work and constant learning," one of the most meaningful aspects of their experience was helping build GRAIL's data platform and real-world evidence capabilities while continuing to "learn, grow and be constructively challenged every day."
- Investing in the future of cancer care: GRAIL continues investing in research, technology and clinical evidence to expand the reach of multi-cancer early detection. As one company leader shared, "As we look ahead, our focus remains on expanding our novel technology to help shift the paradigm of cancer screening to find cancers earlier to potentially improve cancer care and outcomes." This long-term commitment reflects GRAIL's goal of improving cancer care for patients around the world.
- External signals:
- Expanding access to screening: GRAIL continues to partner with leading health systems and healthcare organizations to make multi-cancer early detection available to more eligible patients, extending the potential reach of earlier cancer detection beyond traditional screening programs. (Fierce Healthcare)
- Driving industry collaboration: Independent healthcare coverage highlights GRAIL's collaborations with providers, researchers and health systems to generate the clinical evidence needed to support broader adoption of multi-cancer early detection. (GenomeWeb; MedTech Dive)
Bottom line: GRAIL makes a difference by combining scientific innovation, large-scale clinical research and strategic partnerships to advance earlier cancer detection. Through its technology, clinical evidence programs and collaborations with healthcare organizations around the world, the company is working to improve cancer outcomes while giving employees the opportunity to contribute to a mission with lasting societal impact.
GRAIL Employee Perspectives
GRAIL's mission to detect cancer earlier and improve patient outcomes is a powerful source of motivation for employees. Team members describe being driven by the opportunity to make a meaningful impact on people's lives, inspiring them to tackle complex challenges and work toward expanding access to life-saving technology.
“Everybody here just works so incredibly hard. And if you start to think about it, it is the mission that is at the core of what is driving our people to literally grind through days, grind through weeks, and really get this out to the masses.”
GRAIL's mission resonates deeply with employees who are motivated by the opportunity to make a meaningful difference in people's lives. Team members describe joining the company because they believe advancing early cancer detection can help spare families from the devastating impact of a cancer diagnosis and create better outcomes for patients around the world.
“Like many others, I had a family member who was diagnosed with cancer and passed away last year. I remember thinking to myself when I was considering joining GRAIL, ‘If I can help even one family not go through what my family just went through, by finding cancer early when it can be cured, what better way is there to spend my time?’ I’m very excited to be here and contribute to this mission.”
